UBS Maintains Buy on Versigent, Lowers Price Target to $55

Benzinga Newsdesk www.benzinga.com Negative 66.6%

Neg 66.6% Neu 0% Pos 0%

UBS analyst Joseph Spak maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $58 to $55.

Comments

No comments yet. Be the first!